compound glp-1 fda says that the shortage is over What Patients Need to Know

At 48 hours, more patients improved in shock in group 1 (87%vs.63.6% p=0.3), with a reduced incidence of early deaths at day 14 (22.6% 48.5% p =0.03)

For example, since 2018, spending on Ozempic increased 34 times while spending on Trulicity increased 1.7 times, as shown in the graph below

Popular treatments approved by the FDA include Sales for Lillys GLP-1 treatments reached $40 billion in 2025, accounting for 62% of the companys annual revenue

Navigating GLP-1 information requires separating anecdotal reports from evidence-based guidance

These medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

It is always better to wait for a replacement than to inject a compromised substance